Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 5/2016

01-05-2016 | Literatur kommentiert

Verzicht auf die adjuvante Radiotherapie beim duktalen Carcinoma in situ

12-Jahres-Daten der ECOG-ACRIN E5194-Studie

Authors: Dr. med. David Krug, Prof. Dr. med. Rainer Souchon

Published in: Strahlentherapie und Onkologie | Issue 5/2016

Login to get access

Auszug

Bestimmung des Lokalrezidivrisikos bei Patientinnen mit duktalem Carcinoma in situ (DCIS) in der Beobachtungszeit von 12 Jahren nach Tumorexzision unter Verzicht auf eine postoperative Radiotherapie. …
Literature
1.
Solin LJ, Gray R, Hughes LL et al (2015) Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study. J Clin Oncol 33:3938–3944CrossRefPubMed
2.
Early Breast Cancer Trialists’ Collaborative Group [EBCTCG] (2010) Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst 2010:162–177CrossRef
3.
Morrow M, Katz SJ (2015) Addressing Overtreatment in DCIS: what should physicians do now? J Natl Cancer Inst 107:djv290CrossRefPubMed
4.
Subhedar P, Olcese C, Patil S et al (2015) Decreasing recurrence rates for ductal carcinoma in situ: analysis of 2996 women treated with breast-conserving surgery over 30 years. Ann Surg Oncol 22:3273–3281CrossRefPubMed
5.
6.
Solin LJ, Gray R, Baehner FL et al (2013) A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 105:701–710CrossRefPubMedPubMedCentral
7.
McCormick B, Winter K, Hudis C et al (2015) RTOG 9804: A prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol 33:709–715CrossRefPubMedPubMedCentral
8.
Souchon R (2015) Radiotherapy also for good-risk ductal carcinoma in situ? Results from a prospective randomized RTOG trial. Strahlenther Onkol 191:536–538CrossRefPubMed
9.
Pahl R, Dunst J (2015) Adjuvant radiotherapy significantly also reduces local recurrence rate for prognostically favorable DCIS. Strahlenther Onkol 191:997–999CrossRefPubMed
Metadata
Title
Verzicht auf die adjuvante Radiotherapie beim duktalen Carcinoma in situ
12-Jahres-Daten der ECOG-ACRIN E5194-Studie
Authors
Dr. med. David Krug
Prof. Dr. med. Rainer Souchon
Publication date
01-05-2016
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 5/2016
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-016-0966-z

Other articles of this Issue 5/2016

Strahlentherapie und Onkologie 5/2016 Go to the issue

Original Article

Towards clinical implementation of ultrafast combined kV-MV CBCT for IGRT of lung cancer

Laudatio

Professor Dr. Werner Bohndorf zum 90. Geburtstag

Original Article

Baseline status and dose to the penile bulb predict impotence 1 year after radiotherapy for prostate cancer

Original Article

Treatment of breast cancer with simultaneous integrated boost in hybrid plan technique

Review Article

Adenosine can thwart antitumor immune responses elicited by radiotherapy

Original Article

4D-Listmode-PET-CT and 4D-CT for optimizing PTV margins in gastric lymphoma